Last, Enhertu has a short half-life and is quickly cleared from the blood, which reduces the side effects of its highly toxic payload.

An unassuming painkiller that most people have in their cupboard could help prevent the spread of cancer. Experts might have cracked a groundbreaking – and affordable – aid in the fight against cancer ...

In a phase 2 study, 52% of patients treated with Bria-IMT plus a checkpoint inhibitor for metastatic breast cancer were alive at one year.

The move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.

After breaking through in 2022, with an endorsement for Enhertu to become the first treatment for HER2-low metastatic breast cancer, the question became: How low could Enhertu go?

Narrow-moat Daiichi Sankyo’s third-quarter earnings were in line with our expectations. Despite its change in development strategy for recently approved Datroway (formerly known as Dato-DXd), we ...